English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, July 17, 2019
エーザイ、抗がん剤「ハラヴェン(R)」が局所進行性または転移性乳がんに係る適応で中国当局より承認を取得
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Thursday, July 11, 2019
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
エーザイ、アルツハイマー病協会国際会議2019(AAIC2019)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に18年連続で選定
Wednesday, July 10, 2019
エーザイ、全く新しい創薬アプローチによる革新的認知症治療薬の創出をめざすG2D2が米国マサチューセッツ州ケンブリッジにおいて本格稼働
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
Monday, July 8, 2019
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
エーザイ、ダンディー大学とがん治療薬創出に向けた標的タンパク質分解誘導に関する共同研究契約を締結

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575